Douglas Fair
· Associate Professor (Clinical)University of Utah · Hematology & Oncology
Active 2015–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Dr. Douglas Fair is an Associate Professor of Pediatrics in the Division of Hematology/Oncology at the University of Utah. He received his medical degree from Albany Medical College, completed his Pediatric residency at UT Southwestern in Austin at Dell Children’s Hospital, and his Pediatric Hematology/Oncology Fellowship at the University of Utah. He also received additional training in Clinical Research through the Masters of Science in Clinical Investigation Program at the University of Utah and holds a Utah Certificate of Palliative Education (UCoPE). Dr. Fair joined the university faculty in 2016 and serves as the Director of the Primary Children’s Hospital Solid Tumor Program. He is the Founder and Medical Director of the Childhood, Adolescent, and Young Adult (AYA) Cancer Survivorship Program at Primary Children’s Hospital, and he serves as the Director of the Huntsman Cancer Institute AYA Program and co-Medical Director of the Huntsman Intermountain Adolescent and Young Adult Program (HIAYA). His research interests include improving survival outcomes for children and AYAs diagnosed with solid tumors, clinical trial development for sarcomas and rare tumors, and investigating outcomes and care for survivors of pediatric and AYA cancer. Additionally, he focuses on gonadal and fertility function in cancer survivors, exploring gonadal toxic and protective agents in cancer therapy. Dr. Fair has contributed significantly to national committees and steering groups, including…
Research topics
- Family medicine
- Medicine
- Internal medicine
- Oncology
- Political Science
- Intensive care medicine
- Gerontology
- Medical education
- Demography
- Immunology
Selected publications
Journal of the National Comprehensive Cancer Network · 2023 · 126 citations
This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, inclu…
A View from the past into our collective future: the oncofertility consortium vision statement
Journal of Assisted Reproduction and Genetics · 2021 · 52 citations
PURPOSE: Today, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium. METHODS: The Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproduc…
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 46 citations
Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of neuroblastoma. The information in these guidelines was developed by the NCCN Neuroblastoma Panel, a multidisciplinary group of representatives with expertise in neuroblastoma, consisting of pediatric oncologists, radiologists, pathologists, surgeons, and radiation oncologi…
COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors
JNCI Cancer Spectrum · 2021 · 34 citations
The study objective was to identify sociodemographic and coronavirus disease 2019 (COVID-19) factors that are associated with COVID-19 vaccine hesitancy among adolescent and young adult (AYA) cancer survivors. Eligible participants were 18 years or older and were diagnosed with cancer as an AYA (ages 15-39 years) and received services through an AYA cancer program. A total of 342 participants completed a cross-sectional survey. Our primary outcome-COVID-19 vaccine hesitancy-was surveyed as a 5-p…
JCO Oncology Practice · 2023-12-07 · 32 citations
articleOpen accessPURPOSE Adolescents and young adults (AYAs; age 18-39 years) with cancer report needing support with health insurance. We conducted a pilot randomized controlled trial to assess the feasibility and acceptability of a virtual health insurance navigation intervention (HIAYA CHAT) to improve health insurance literacy (HIL), awareness of Affordable Care Act (ACA) protections, financial toxicity, and stress. MATERIALS AND METHODS HIAYA CHAT is a four-session navigator delivered program; it includes p…
Frequent coauthors
- 96 shared
Anne C. Kirchhoff
- 71 shared
Echo L. Warner
University of Utah
- 69 shared
Heydon K. Kaddas
- 43 shared
Austin R. Waters
University of Utah
- 39 shared
Perla L. Vaca Lopez
University of Utah
- 39 shared
Judy Y. Ou
University of Utah
- 38 shared
Nicole Ray
University of Utah
- 33 shared
Joemy M. Ramsay
University of Utah
Education
M.D.
Albany Medical College
Other, Pediatric Hematology/Oncology
University of Utah
M.S., Clinical Investigation
University of Utah
Other, Palliative Education (UCoPE)
Utah
Awards & honors
- Utah Certificate of Palliative Education (UCoPE)
- Fellow of the American Academy of Pediatrics (FAAP)
Similar researchers at University of Utah
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Douglas Fair
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup